As a physician-scientist and a board-certified medical oncologist, I devote my career to the improvement of kidney cancer care. My primary clinical interest is aggressive kidney cancer with a special focus on rare subtypes. I founded the MSK Translational Kidney Cancer Research Program (TKCRP) in 2011 with Robert Motzer and Paul Russo. The TKCRP aims to directly decode the molecular basis underlying disease aggressiveness and treatment response/resistance to targeted therapies. The overarching goal of our program is to develop personalized treatment regimens for the cure of metastatic kidney cancer patients.
I am a member of the American Society for Clinical Investigation, and my laboratory in the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center focuses on constructing the molecular blueprint of cancers and developing novel cancer therapeutics.
- Clinical Expertise: Kidney Cancer
- Languages Spoken: English
- Education: MD, Taipei Medical University; PhD, Johns Hopkins School of Medicine
- Residencies: Barnes-Jewish Hospital, Washington University School of Medicine
- Fellowships: Barnes-Jewish Hospital, Washington University School of Medicine; Dana-Farber Cancer Institute, Harvard Medical School
- Board Certifications: Medical Oncology
As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.Learn more
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more